Ipsen sells pri­or­i­ty re­view vouch­er for high­est price since 2016

Ipsen Phar­ma­ceu­ti­cals sold its pri­or­i­ty re­view vouch­er to an uniden­ti­fied “large glob­al phar­ma­ceu­ti­cal com­pa­ny” for $158 mil­lion, it said this week, the high­est pub­licly an­nounced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER